BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38163647)

  • 1. Extracellular α-synuclein impairs sphingosine 1-phosphate receptor type 3 (S1PR3)-regulated lysosomal delivery of cathepsin D in HeLa cells.
    Nishida S; Matovelo SA; Kajimoto T; Nakamura SI; Okada T
    Genes Cells; 2024 Mar; 29(3):207-216. PubMed ID: 38163647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular α-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling.
    Badawy SMM; Okada T; Kajimoto T; Hirase M; Matovelo SA; Nakamura S; Yoshida D; Ijuin T; Nakamura SI
    J Biol Chem; 2018 May; 293(21):8208-8216. PubMed ID: 29632069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact.
    Zhang L; Okada T; Badawy SMM; Hirai C; Kajimoto T; Nakamura SI
    Sci Rep; 2017 Mar; 7():44248. PubMed ID: 28300069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy.
    Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG
    Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
    Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
    Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils.
    Tsujimura A; Taguchi K; Watanabe Y; Tatebe H; Tokuda T; Mizuno T; Tanaka M
    Neurobiol Dis; 2015 Jan; 73():244-53. PubMed ID: 25466281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.
    McGlinchey RP; Lee JC
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9322-7. PubMed ID: 26170293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.
    Dong WL; Zhong JH; Chen YQ; Xie JF; Qin YY; Xu JP; Cai NB; Li MF; Liu L; Wang HT
    Acta Pharmacol Sin; 2021 Dec; 42(12):1991-2003. PubMed ID: 34531546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells.
    Crabtree D; Dodson M; Ouyang X; Boyer-Guittaut M; Liang Q; Ballestas ME; Fineberg N; Zhang J
    J Neurochem; 2014 Mar; 128(6):950-61. PubMed ID: 24138030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
    Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
    Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M
    Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Protease Cathepsin D and Upregulation of Pathologic α-Synuclein Mediate Paucity of DNAJC6-Induced Degeneration of Dopaminergic Neurons.
    Chiu CC; Chen YL; Weng YH; Liu SY; Li HL; Yeh TH; Wang HL
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
    Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
    J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.
    Nelson MP; Boutin M; Tse TE; Lu H; Haley ED; Ouyang X; Zhang J; Auray-Blais C; Shacka JJ
    Neurobiol Dis; 2018 Feb; 110():68-81. PubMed ID: 29196214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.
    Matrone C; Dzamko N; Madsen P; Nyegaard M; Pohlmann R; Søndergaard RV; Lassen LB; Andresen TL; Halliday GM; Jensen PH; Nielsen MS
    PLoS One; 2016; 11(8):e0160501. PubMed ID: 27509067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.